FindTrial
Sign In

In infertile women, ovarian stimulation is used to induce the production of multiple ova and the known complication is painful ovarian enlargement-ovarian hyperstimulation syndrome.we aim to compare the effectiveness and outcomes of a multidrug regimen versus treatment with elagolix

An observational study evaluating the efficacy of elagolix versus multi-drug regimen for the prevention of ovarian hyperstimulation syndrome (OHSS) - OHSS trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087630
Enrollment
100
Registered
2025-05-26
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 1- Obstetrics

Interventions

Intervention1: Elagolix: gonadotropin-releasing hormone antagonist (GnRH antagonist) medications 8 months Control Intervention1: Multidrug regimen- ELAGOLIX, ANASTRAZOLE , CABERGOLINE: ELAGOLIX- GnRH

Sponsors

Suresh Viswanathan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: antagonist protocol, dual trigger (agonist and HCG 1500 to 2000), E2 on trigger day greater than 3000, number of oocytes greater than 15

Exclusion criteria

Exclusion criteria: age ( less than 21 years), and (greater than 40years), E2 greater than 6000

Design outcomes

Primary

MeasureTime frame
prevention of OHSS and its severityTimepoint: oocyte retrieval day to 10 days—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactSindhumathi R

S.K.S Hospital and post graduate medical institute

drkaviprakash@gmail.com9003640114

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026